GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » PetVivo Holdings Inc (OTCPK:PETVW) » Definitions » Net Income Including Noncontrolling Interests

PetVivo Holdings (PetVivo Holdings) Net Income Including Noncontrolling Interests : $-10.63 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is PetVivo Holdings Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

PetVivo Holdings's Net Income Including Noncontrolling Interests for the three months ended in Dec. 2023 was $-1.75 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Dec. 2023 was $-10.63 Mil.


PetVivo Holdings Net Income Including Noncontrolling Interests Historical Data

The historical data trend for PetVivo Holdings's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PetVivo Holdings Net Income Including Noncontrolling Interests Chart

PetVivo Holdings Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.76 -2.08 -3.52 -5.02 -8.72

PetVivo Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.31 -2.33 -2.89 -3.66 -1.75

PetVivo Holdings Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.63 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PetVivo Holdings Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of PetVivo Holdings's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.


PetVivo Holdings (PetVivo Holdings) Business Description

Industry
Traded in Other Exchanges
Address
5251 Edina Industrial Boulevard, Edina, MN, USA, 55439
PetVivo Holdings Inc is an emerging biomedical device company. The group is focused on the manufacturing, commercialization, and licensing of medical devices and therapeutics for companion animals. A key strategy of the company is to leverage human therapies for the treatment of companion animals cost-effectively and in a timely manner. The accelerated timeline to revenues for veterinary medical devices is a key component of this strategy, which enter the market much earlier than pharmaceuticals and biologics. The product pipeline includes approximately seventeen products intended to treat animals and people. Its patent protection extends to biomaterials, products, production processes, and methods of use provided by the company's portfolio of nineteen patents.